Literature DB >> 7490131

Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.

B Martinez-Kinader1, G B Lipford, H Wagner, K Heeg.   

Abstract

Immunization with exogenous proteins usually fails to immunize CD8+ T cells in vivo. Here we report that chicken ovalbumin (OVA) denatured by heat or sodium dodecyl sulphate (SDS) effectively induced CD8+ cytolytic T cells in vivo. The cytolytic T-lymphocyte (CTL) population generated recognized syngeneic target cells pulsed with the immunodominant OVA peptide (257-264) or transfected with the OVA protein-encoding gene. To analyse the mechanisms of how denatured OVA enters the class I-restricted pathway of antigen presentation, we took advantage of the fact that denatured OVA sensitizes target cells in vitro for lysis by OVA-specific CTL. We found that neither inhibition of protein synthesis (by cycloheximide) nor blocking of transport via the Golgi apparatus (by brefeldin A) interfered with the class I-restricted presentation of denatured OVA in vitro. In addition, transporter associated with antigen presentation (TAP)-dependent transport into the endoplasmic reticulum (ER) was not required for effective presentation, as TAP-deficient cells (RMA-S) could be sensitized effectively by denatured OVA for recognition by class I-restricted CTL. In contrast, class I-restricted presentation of denatured OVA was sensitive to lysosomotropic agents (NH4Cl, vinblastine and leupeptin), indicating that endosomal-like compartments are involved in the presentation of denatured OVA. Sensitization was inhibited at low temperature, yet took place in the presence of sucrose and in the absence of K+, indicating that denatured OVA enters the cell via fluid-phase endocytosis. Hence the results provide further evidence for an alternative class I-restricted pathway of antigen presentation for exogenous proteins. As that pathway seems to be effective in vivo, it offers a new and effective way of vaccination of CD8+ CTL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490131      PMCID: PMC1384008     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments.

Authors:  P A Reid; C Watts
Journal:  Nature       Date:  1990-08-16       Impact factor: 49.962

2.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Cytotoxic T lymphocytes against a soluble protein.

Authors:  U D Staerz; H Karasuyama; A M Garner
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

4.  Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation.

Authors:  J G Nuchtern; J S Bonifacino; W E Biddison; R D Klausner
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

5.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

6.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules.

Authors:  M Kovacsovics-Bankowski; K L Rock
Journal:  Science       Date:  1995-01-13       Impact factor: 47.728

7.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

Authors:  H Takahashi; T Takeshita; B Morein; S Putney; R N Germain; J A Berzofsky
Journal:  Nature       Date:  1990-04-26       Impact factor: 49.962

8.  Depletion of intracellular potassium arrests coated pit formation and receptor-mediated endocytosis in fibroblasts.

Authors:  J M Larkin; M S Brown; J L Goldstein; R G Anderson
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

9.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  Endocytosis of the class I major histocompatibility antigen via a phorbol myristate acetate-inducible pathway is a cell-specific phenomenon and requires the cytoplasmic domain.

Authors:  G G Capps; M Van Kampen; C L Ward; M C Zúñiga
Journal:  J Cell Biol       Date:  1989-04       Impact factor: 10.539

View more
  7 in total

1.  CD8+ T cells have an essential role in pulmonary clearance of nontypeable Haemophilus influenzae following mucosal immunization.

Authors:  A R Foxwell; J M Kyd; G Karupiah; A W Cripps
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

3.  Quantitative analysis of the immunopotency of genetically transfected dendritic cells.

Authors:  L Timares; A Takashima; S A Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 4.  Plasmid DNA vaccination: mechanism of antigen presentation.

Authors:  M Corr; H Tighe
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Capsid-specific cytotoxic T lymphocytes recognize three distinct H-2D(b)-restricted regions of the BeAn strain of Theiler's virus and exhibit different cytokine profiles.

Authors:  Michael A Lyman; Hee-Gu Lee; Bong Su Kang; Hee-Kap Kang; Byung S Kim
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Gene vaccination with naked plasmid DNA: mechanism of CTL priming.

Authors:  M Corr; D J Lee; D A Carson; H Tighe
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

7.  Innovative DNA vaccine to break immune tolerance against tumor self-antigen.

Authors:  Tae Heung Kang; Chih-Ping Mao; Victor La; Alexander Chen; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.